Switzerland· 66472001
Maviret Filmtabletten
A glecaprevir and pibrentasvir product containing glecaprevirum, pibrentasvirum, registered in Switzerland by AbbVie AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Glecaprevir and pibrentasvir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Glecaprevir and pibrentasvir · ATC J05AP57
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- glecaprevirum, pibrentasvirum
- Manufacturer
- AbbVie AG
- Country
- Switzerland (CH)
- ATC code
- J05AP57
- ATC class
- Glecaprevir and pibrentasvir
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768066472001384 StkCHF 13798.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glecaprevir and pibrentasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomGlecaprevir 100mg / Pibrentasvir 40mg tabletsAbbVie Ltd
- United StatesMavyretAbbVie Inc.
- SpainMAVIRET 100 MG/40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAbbvie Deutschland Gmbh & Co. Kg
- FinlandMaviretAbbVie Deutschland GmbH&Co.KG
- FranceMAVIRET 100 mg/40 mg, comprimé pelliculéABBVIE DEUTSCHLAND (ALLEMAGNE)
- CanadaMAVIRETABBVIE CORPORATION
- IcelandMaviretAbbVie Deutschland GmbH & Co. KG
- NetherlandsMaviret 100 mg/40 mg filmomhulde tablettenAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
- Iceland · Maviret
- Liechtenstein · Maviret
- Norway · Maviret
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c697c6f9-689d-4378-9801-e2c2110b87c8 GET /v1/drugs/c697c6f9-689d-4378-9801-e2c2110b87c8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "glecaprevirum 100 mg + pibrentasvirum 40 mg",
"valid_from": "2022-01-01",
"limitations": "[{\"description\":\"Zur Behandlung der chronischen Hepatitis C (CHC) Genotyp 1‐6 bei Erwachsenen und Jugendlichen ab 12 Jahren.<br>\\nIst eine 12- oder 16‐wöchige Behandlung mit MAVIRET erforderlich, vergütet die AbbVie AG nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, den Fabrikabgabepreis der dritten/vierten, nachweislich verabreichten Packung à je Fr. 13’148.57 zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Betrag zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20698.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\"}]",
"galenic_form": "Filmtabl 100mg/40mg",
"therapeutic_area": null,
"sl_inclusion_date": "2017-12-01",
"self_retention_pct": 10
}See everything about glecaprevir and pibrentasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.